WATERTOWN -
The meeting will be held
'We are honored to have our KT-621 BroADen Phase 1b data selected for a late-breaking oral presentation at AAD,' said
AAD 2026 Late-Breaking Presentation Details
Abstract Title: Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results
Session Title:
Session Type: Oral Presentation
Presentation Date/Time:
Location:
A copy of the presentation will be available in the
About KT-621
KT-621 is an investigational, first-in-class, once-daily oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently being evaluated in parallel Phase 2b clinical trials in atopic dermatitis (BROADEN2) and asthma (BREADTH). By selectively targeting STAT6 for degradation, KT-621 has the potential to provide a novel oral approach for patients living with Type 2 inflammatory diseases, which affect more than 140 million people worldwide.
About
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on the development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target,' 'upcoming' and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: that preclinical and clinical data, including the results from the Phase 1 trials of KT-621, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate, uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development, and other factors. These risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the
Contact:
Email: investors@kymeratx.com
Tel: 857-285-5300
Email: mhenson@kymeratx.com
Tel: 857-285-5300
(C) 2026 Electronic News Publishing, source
